<DOC>
	<DOC>NCT00201786</DOC>
	<brief_summary>This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.</brief_summary>
	<brief_title>Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>Must have biopsy proven grade IIIV acute GVHD refractory to systemic corticosteroids No chronic GVHD Age ≥ 18 years Evidence of myeloid engraftment (ANC ≥ 0.5 x 109/l) Performance status 03 Patients on mechanical ventilation or who have resting O2 saturation &lt;90% by pulseoximetry. Patients on renal dialysis or who have an estimated creatinine clearance of &lt; 30 ml/min/1.73 m2. Patients with documented clinical infection (progressive symptoms despite antibiotics or continued fever) cannot be enrolled on study until infection is controlled.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Corticosteroids</keyword>
</DOC>